Visual acuity outcomes in diabetic macular edema with fluocinolone acetonide 0.2 µg/day versus ranibizumab plus deferred laser (DRCR protocol I)

Michael A. Singer*, Dan M. Miller, Jeffrey G. Gross, Craig M. Greven, Barry Kapik, Clare Bailey, Faruque Ghanchi, Baruch D. Kuppermann

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

4 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: Visual outcomes of the FAME study (0.2 µg/day fluocinolone acetonide [FAc]) and Protocol I (0.5 mg ranibizumab plus deferred laser) were compared using the area under the curve (AUC) analysis method. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) data collected during a period of 3 years of follow-up for patients enrolled in FAME or Protocol I were used to calculate AUC of the change in BCVA over a time curve. RESULTS: In the overall population, there was a greater treatment effect for ranibizumab plus deferred laser compared with FAc. However, for subgroups of pseudophakic eyes, eyes with chronic diabetic macular edema (DME), and pseudophakic eyes with chronic DME, ranibizumab plus deferred laser and FAc were not found to be significantly different. The ranibizumab group received a median of 14 injections during a 36-month period compared with a mean of 1.3 injections in the FAc group. CONCLUSION: In pseudophakic and chronic DME subgroups, FAc was comparable to ranibizumab plus deferred laser with fewer injections.

Original languageEnglish
Pages (from-to)698-706
Number of pages9
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume49
Issue number9
DOIs
Publication statusPublished - 1 Sep 2018

Fingerprint Dive into the research topics of 'Visual acuity outcomes in diabetic macular edema with fluocinolone acetonide 0.2 µg/day versus ranibizumab plus deferred laser (DRCR protocol I)'. Together they form a unique fingerprint.

Cite this